BioMS Medical to continue phase 2/3 multiple sclerosis trial

By Elaine Rigoli

Tampa, Fla., Aug. 16 - BioMS Medical Corp. said Wednesday that it has received a recommendation to continue its pivotal phase 2/3 clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.

The study is now ongoing at trial sites across Canada, the United Kingdom, Sweden, Denmark and the Netherlands.

This was the fifth of several regularly scheduled reviews by the data safety monitoring board that will occur over the duration of the trial, the company said in a news release.

The purpose of the board is to provide objective, independent safety monitoring of the trial.

BioMS Medical is a biotechnology company located in Edmonton, Alta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.